References
- Howell A. The future of fulvestrant (faslodex). Cancer Treat Rev 2005; 31(Suppl 2)S26–33
- Buzdar A U. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today 2004; 40: 751–764
- Levesque C, Merand Y, Dufour J M, Labrie C, Labrie F. Synthesis and biological activity of new halo-steroidal anti-estrogens. J Med Chem 1991; 34: 1624–1630
- Wakeling A, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867–3873
- Dodwell D, Vergote I. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second line treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rev 2005; 31: 274–282
- Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor positive breast cancer. Cancer Invest 2005; 23: 173–181
- Buzdar A U, Robertson J F. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother 2006; 40: 1572–1583
- Dew J E, Wren B G, Eden J A. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer, a cohort study. Climacteric 2002; 5: 151–155
- Habel L A, Stanford J L. Hormone receptors and breast cancer. Epidemiol Rev 1993; 15: 209–219
- Di Saia P J. Hormone replacement therapy for breast cancer survivors: facts versus fears. Clin Oncol 1995; 7: 241–245
- Howell A, Osbourne C K, Robertson J FR, et al. ICI 182,780 (faslodex) versus anastrozole(Arimidex) for the treatment of advanced breast cancer in postmenopausal women – prospective combined analysis of two multicenter trials. Eur J Cancer 2001; 37(Suppl 5)9, abstr 1-24
- Werner H MJ, Franke H R, Vermes I. Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs. Climacteric 2005; 8: 294–299
- Marx P TJ, Mulder A B, Bergh F AJTM, et al. Apoptosis induces endotoxin and Fas-ligation enhances the expression of vascular endothelial growth factor in human endothelial cells. Endothelium 1999; 6: 335–340
- Heid C A, Stevens J, Livak K J, Williams P M. Real time quantitative PCR. Genome Res 1996; 6: 986–994
- Nicoletti I, Migliorati G, Pagliacci M C, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271–279
- Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000; 243: 167–190
- Holmberg L, Anderson H. HABITS (Hormone replacement therapy after breast cancer – is it safe), a randomised comparison: trial stopped. Lancet 2004; 364: 453–455
- Seeger H, Wallwiener D, Mueck A O. Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of breast cancer cells. J Br Menopause Soc 2003; 9: 36–38
- Von Schoultz E, Rutqvist L E. Menopausal hormone therapy after breast cancer: The Stockholm randomised trial. J Natl Cancer Inst 2005; 97: 533–535
- Chlebowski R T, Hendrix S L, Langer R D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003; 289: 3243–3253
- Rippy L, Marsden J. Is HRT justified for symptom management in women at higher risk of developing breast cancer?. Climacteric 2006; 9: 404–415
- Bonanni B, Guerrieri-Gonzaga A, Rotmenssz N, Torrisi R. Hormonal therapy and chemoprevention. Breast J 2000; 6: 317–323
- Schuetz F, Diel I J, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 2007; 196, 342.e1–9
- Franke H R, Vermes I. Differential effect of progestagens on breast cancer cell lines. Maturitas 2003; 46(Suppl 1)S55–S58
- Verdijk R, Franke H R, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Letters 2007; 246: 308–312
- Wolbers F. Apoptosis chip for drug screening, thesis. 2007, ISBN 987-90-365-2499-5